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Abstract
Introduction: Chemotherapy-associated osteonecrosis of the jaw caused by bisphosphonates is an exposure of 
necrotic bone with more than eight weeks of evolution that is attributable to bisphosphonates and no prior radia-
tion therapy. Its etiopathogenesis remains unknown, although there are two hypotheses that may explain it: the 
drug’s mechanism of action, and the risk factors that can lead to osteonecrosis. There is a wide range of treatment 
options for managing chemotherapy-associated osteonecrosis of the jaw, from conservative treatments to surgical 
procedures of varying levels of invasiveness, which are sometimes supplemented with adjuvant therapies.
Objectives: The objective of this article is to group the therapeutic options for osteonecrosis of the jaw (ONJ) into 
seven different protocols and to evaluate their effectiveness in relation to stage of ONJ. 
Material and Methods: A literature review was carried out in PubMed following the PRISMA criteria. A total of 
47 were collected after compiling a series of variables that define ONJ, applied treatments, and the clinical results 
obtained.
Results and Discussion: The 47 articles selected have a low to average estimated risk of bias and are of moderate to 
good quality. According to the data obtained, Protocol 3 (conservative treatment, clinical and radiological follow-
up, minimally invasive surgical treatment, and adjuvant therapies) is the most favorable approach for ONJ lesions 
caused by oral bisphosphonates. For lesions caused by intravenous bisphosphonates, Protocol 2 (conservative 
treatment, clinical and radiological follow-up, minimally invasive surgical treatment, and no adjuvant therapies) 
is the best approach. When comparing the different stages of ONJ, Protocol 1 (conservative treatment, clinical 
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and radiological follow-up) promotes better healing of Stage 1 ONJ lesions caused by orally administered bisphos-
phonates, and Protocol 3 is recommended for Stage II. For ONJ lesions attributable to intravenous bisphosphonates, 
Protocol 7 (conservative treatment, clinical and radiological follow-up, and adjuvant therapies) provides the best 
results in Stage 0; in Stages I, II, and III, Protocol 1 gives better results.
Key words: Bisphosphonates, bronj, therapeutic protocol, clinical result.
Introduction
Bisphosphonates are stable, inorganic pyrophosphate 
analogs that are classified by their route of adminis-
tration (oral or intravenous) and chemical composition 
(nitrogenous and non-nitrogenous). They are indicated 
for metabolic bone diseases (osteoporosis, osteogenesis 
imperfecta, Paget’s disease, etc.) or malignant hypercal-
cemia (multiple myeloma, cervical, lung, or mammary 
cancer, etc.). Many studies have proved their effective-
ness in palliating bone and articular pain and in avoiding 
bone fractures, but due to their mechanism of action, in 
2003, Marx warned of a complication: chemotherapy-
associated osteonecrosis of the jaw (1). 
Chemotherapy-associated osteonecrosis of the jaw re-
fers to an exposure of necrotic bone with more than 
eight weeks of evolution that is attributable to bisphos-
phonates and no prior radiation therapy. Although its 
etiopathogenesis is unknown, two hypotheses could 
explain it: 1) the drug’s mechanism of action, which 
inhibits normal bone remodeling, impairs angiogen-
esis, increases the toxicity of soft tissues, and promotes 
dysfunctional modulation of the immune system; 2) the 
risk factors that trigger ONJ: local factors (oral surgery, 
prosthetic trauma, mandibular or palatal tori, ulcers, 
etc.), systemic and demographic factors (endocrine 
disruption [caused by obesity, diabetes, etc.], tobacco 
use, alcohol consumption, age, race, etc.), and genetic 
factors (cytochrome P450, nucleotide polymorphism 
[SNPs], etc.) (2).  
ONJ encompasses a range of different stages. Depend-
ing on how advanced a stage is, the presence or absence 
of symptomatology, and/or whether there is any expo-
sure of necrotic bone, there are different treatment al-
ternatives indicated for management of chemotherapy-
associated osteonecrosis of the jaw. These alternatives 
are divided into: 1) conservative treatment: antibiotics, 
analgesics, antiseptics, and antifungals; 2) minimally 
invasive surgical treatment (curettage or debridement 
of the exposed area, contouring of sharp bony edges, 
sequestrectomy with or without teeth involvement, etc.) 
or invasive surgical treatment (marginal and segmen-
tal resection with reconstruction of defective bone and 
soft tissues); 3) adjuvant therapies (PRP, laser, BMP, 
teriparatide therapy, ozone therapy, oxygen therapy, 
and photodynamic therapy). Adjuvant therapies will 
promote to a greater or lesser degree the correct healing 
of bone and soft tissues (3). 
As chemotherapy-associated osteonecrosis of the jaw is 
a complex condition, it is problematic not only for den-
tists but also for oral and maxillofacial surgeons; while 
there are many different treatment options, it not always 
clear which approach is the best for any given case.
While the best therapeutic option is simply to prevent 
ONJ from occurring in the first place, once it is diag-
nosed, treatment focuses on healing as well as offer-
ing the patient a better quality of life, focusing not only 
on the lesions but also on the complications they may 
cause.
This article seeks to use published evidence to identify 
the different therapeutic options that can be applied to 
osteonecrosis of the jaw and assess their effectiveness 
according to the stage of the disease in which they are 
applied.
Material and Methods
A review of the literature published in PubMed was 
carried out from January 2002 (the year in which os-
teonecrosis of the jaw was first described) to September 
2015 using the following keywords: “osteonecrosis jaw 
AND surgical approach,” “osteonecrosis jaw AND la-
ser therapy,” “osteonecrosis jaw AND hyperbaric oxy-
gen,” “osteonecrosis jaw AND PRP,” “antibiotic proph-
ylaxis AND osteonecrosis,” “bisphosphonates AND os-
teonecrosis AND dental management,” “osteonecrosis 
jaw AND protocol bisphosphonates,” “osteonecrosis 
jaw AND conservative protocol,” and “osteonecrosis 
jaw AND surgical protocol.”
Searches with these keywords returned 61, 31, 34, 9, 31, 
133, 55, 12, and 44 results, respectively. The following 
inclusion and exclusion criteria were applied.
The inclusion criteria were: 1) academic publications 
written in English that use the clinical diagnosis of os-
teonecrosis of the jaw as established by the AAOMS and 
the ASBMR (4); 2) the following types of studies: clini-
cal trials and case series with more than five patients; 
3) articles that identify the route of administration of 
bisphosphonates, the risks factors for development of 
ONJ, the treatment protocol chosen, and its results. 
The exclusion criteria were: 1) articles that did not 
meet the inclusion criteria; 2) articles unrelated to the 
research topic; 3) articles with less than five human pa-
tients, letters to the editor, and expert opinions.
The automatic search was complemented with a man-
ual verification of all bibliographic references from the 
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collected articles, choosing any additional articles that 
were relevant to the present study and that met the in-
clusion and exclusion criteria used.
A dual approach was used to assess overall quality, with 
each article being evaluated for both risk of bias and 
the total number of variables collected. Table 1 shows 
the criteria used to gauge the risk of bias. Thus, if an 
article has two or three zeros, the risk of uncontrolled 
bias is low; with four zeros, the risk of uncontrolled bias 
is medium, and if an article has more than four zeros, 
the uncontrolled risk of bias is high, and the article will 
consequently be eliminated from the study.
To evaluate the suitability of the variables provided in 
each article, the total number of collected variables was 
assessed using a modification suggested by the AAOMS 
and ASBMR (4). The articles were evaluated using 12 
Evaluates 0 1 2
A Sample size Does not exist Reported but un 
confirmed
Reported and 
confirmed
B
Methods of concealment 
and randomization 
allocation
Clearly inappropriate May be suitable Clearly appropriate
C Clearly defined eligibility criteria No Yes -
D Specific reasons for par-ticipant drop-outs No Not clear Yes/No drop-out
E
Experimental and control 
groups according to im-
portant prognostic factors
No / Not comparable 
due to one or more risk 
factors
Clearly appropriate -
F Masking No Not clear Yes
G Appropriate statistical analysis No Not clear Yes
Tale 1. Risk of bias control assessment. 
parameters involving ONJ and its stage of advancement, 
study design, number of patients, average age, type and 
route of administration of the bisphosphonate, location 
of the ONJ, cause for therapy with bisphosphonates, 
trigger factor/s, risk factors for osteonecrosis, the treat-
ment applied, and the results obtained with this treat-
ment. Depending on the information collected in each 
article, the publication’s quality was classified as good 
(10-12 variables provided), moderate (5-9 variables pro-
vided) or poor (1-4 variables provided).
To reach the proposed objectives, after grouping all the 
aforementioned variables by choice of treatment (con-
servative treatment, minimally invasive surgical treat-
ment, and invasive surgical treatment), defining param-
eters of the clinical approach for each option were col-
lected: 1) conservative treatment: type of mouthwash, 
intraoral gels, antifungal drugs, analgesics, and antibi-
otics used as well as the protocol for discontinuing use, 
if any; 2) minimally invasive surgical treatment: type of 
conservative treatment, type of minimally invasive sur-
gical technique used, and whether it was accompanied 
by any adjuvant therapies; 3) invasive surgical treat-
ment: type of conservative treatment, type of invasive 
surgical treatment used, and whether or not an adjuvant 
therapy was used.
All the data were grouped into seven different proto-
cols, with the results obtained in ONJ lesions also being 
studied after the application of these protocols. The sev-
en protocols are: 1) Protocol 1: conservative treatment, 
clinical and radiological follow-up; 2) Protocol 2: con-
servative treatment, clinical and radiological follow-up, 
minimally invasive surgical treatment without adjuvant 
therapies; 3) Protocol 3: conservative treatment, clinical 
and radiological follow-up, minimally invasive surgical 
treatment, and adjuvant therapies; 4) Protocol 4: con-
servative treatment, clinical and radiological follow-up, 
invasive surgical treatment without adjuvant therapies; 
5) Protocol 5: conservative treatment, clinical and ra-
diological follow-up, invasive surgical treatment, and 
adjuvant therapies; 6) Protocol 6: adjuvant therapies, 
clinical and radiological follow-up; 7) Protocol 7: con-
servative treatment, clinical and radiological follow-up, 
and adjuvant therapies.
A number of synonyms have been found in the selected 
articles regarding the type of clinical results obtained 
after treatment of ONJ lesions. To simplify the results 
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found, a general name has been used for these: com-
plete healing, partial healing (lesion with remission, 
lesion with moderate improvement, stable lesion, and 
non-recurrent lesion) and lesions that become worse 
(recurrent lesion, uncontrolled lesion, worsening lesion, 
lesion that fails to heal, and progressive lesion). These 
three results will be used to evaluate the effectiveness 
of each protocol.
Results
The initial search in PubMed yielded 410 results, with 
an additional 181 articles collected during the manual 
search of bibliographic references (Fig. 1).
The 47 articles selected have a low to average estimated 
risk of bias and are of moderate to good quality. These 
evaluations can be seen in tables 2,3 and 3 continue. 
After selecting the articles, an initial analysis of each 
treatment option assessed the 12 variables of ONJ, as 
well as the seven aforementioned protocols, to produce 
the tables in which the overall results of each protocol 
for ONJ lesions caused by oral bisphosphonates (Table 
4) and intravenous bisphosphonates (Table 5) are de-
tailed. 
Subsequently, the data were analyzed and presented ac-
cording to stage of advancement of the lesion and the 
protocol applied; this analysis can be seen in table 6 and 
6 continue (oral bisphosphonates) and table 7 and 7 con-
tinue (intravenous bisphosphonates). 
Fig. 1. Flowchart of the systematic literature review.
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Discussion
After carrying out the bibliographic search, there ap-
pears to be a substantial amount of heterogeneity among 
the mentioned techniques and great controversy over 
which protocols are the best, with various results in the 
effective management of ONJ found (5-7). 
The results of the seven evaluated protocols on lesions 
produced by osteonecrosis of the jaw can be used to pre-
dict which protocol will obtain better or worse results, 
both overall and in each individual stage (differentiat-
ing as well between the various routes of administration 
employed).
With regard to the overall effectiveness of the seven 
protocols in the treatment of ONJ lesions caused by 
Table 2. Evaluation of risk of bias and usefulness of the selected publications using oral bisphosphonates.
  A(0-2) B(0-2) C(0-2) D(0-2) E(0-2) F(0-2) G(0-2) Risk Assessment 
Quality of publication according to 
collected variables 
Longobardi et al. 
(39) 2007  1 0 1 1 1 0 0 Low 
12 variables collected:  
Good quality 
Vescovi et al. (23) 
2007  2 0 1 1 2 0 0 Low 
9 variables collected: 
Moderate quality  
Stanton et al. (40) 
2009  1 0 1 1 1 0 0 Low 
9 variables collected: 
Moderate quality 
Junquera et al. (19) 
2009  1 0 0 1 1 0 1 Low 
12 variables collected: 
Good quality 
Alons et al. (20) 
2009  1 0 1 1 1 0 0 Low 
12 variables collected: 
Good quality 
Saussez et al. (21) 
2009  1 0 0 1 1 0 2 Low 
11 variables collected: 
Good quality 
Epstein et al. (22) 
2010  1 0 0 1 1 0 0 Medium  
9 variables collected: 
Moderate quality 
Williamson et al. 
(18) 2010  1 0 0 1 1 0 0 Medium  
10 variables collected: 
Good quality 
Kos et al. (41)  
2010  2 0 0 1 2 0 2 Low 
12 variables collected: 
Good quality 
Seth et al. (8)  
2010  1 0 0 1 1 0 0 Medium  
8 variables collected: 
Moderate quality 
Hoefert et al. (42) 
2011  2 0 0 1 2 0 1 Low 
11 variables collected: 
Good quality 
Vescovi et al. (43) 
2011  2 0 1 1 2 0 2 Low 
10 variables collected: 
Good quality 
Bedogni et al. (37) 
2011  1 0 1 1 1 0 2 Low 
11 variables collected: 
Good quality 
Manfredi et al. (16) 
2011  2 0 1 1 2 0 0 Low 
11 variables collected: 
Good quality 
Jabbour et al. (44) 
2012  1 0 1 1 1 0 1 Low 
10 variables collected: 
Good quality  
Wutzl et al. (9)  
2012  1 0 1 1 1 0 2 Low 
10 variables collected: 
Good quality 
Schafer et al. (15) 
2012  1 1 1 1 1 0 2 Low 
6 variables collected: 
Moderate quality 
Ferlito et al. (45) 
2012  1 0 1 1 1 0 2 Low 
9 variables collected: 
Moderate quality 
Schubert et al. (46) 
2012  2 0 1 1 2 0 0 Low 
7 variables collected: 
Moderate quality 
Bocanegra-Pérez  
et al. (24) 2012  1 0 1 1 2 0 0 Low 
11 variables collected: 
Good quality 
Martins et al. (25) 
2012  2 0 1 1 2 0 2 Low 
12 variables collected: 
Good quality 
Vescovi et al. (26) 
2012  2 0 0 1 2 0 2 Low 
12 variables collected: 
Good quality 
Beninati et al. (47) 
2013  1 0 1 1 1 0 0 Low 
10 variables collected: 
Good quality 
Holzinger et al. (48) 
2013  1 0 1 1 1 0 2 Low 
8 variables collected: 
Moderate quality 
Anavi-Lev et al. (49) 
2013  1 0 0 1 1 0 2 Low 
10 variables collected: 
Good quality 
Blus et al. (10)  
2013  1 0 1 1 1 0 0 Low 
12 variables collected: 
Good quality 
Rugani et al. (36) 
2013  1 0 0 1 1 0 0 Medium  
9 variables collected: 
Moderate quality 
Longo et al. (27) 
2014  1 0 0 1 1 0 2 Low 
8 variables collected: 
Moderate quality 
Rugani et al. (17) 
2014  2 0 1 1 2 0 0 Low 
8 variables collected: 
Moderate quality 
Pelaz et al. (28) 
2014  1 0 1 1 2 0 0 Low 
11 variables collected: 
Good quality 
!
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  A(0-2) 
 
B(0-2) 
 
C(0-2) 
 
D(0-2) 
 
E(0-2) 
 
F(0-2) 
 
G(0-2) 
Risk 
Assessment 
Quality of publication 
according to collected 
variables 
Badros et al. (11) 
2006  1 0 0 1 1 0 2 Low 
12 variables collected: 
Good quality  
Longobardi et al. (39) 
2007  1 0 1 1 1 0 0 Low 
12 variables collected: 
Good quality 
Freiberger et al. (29) 
2007  1 0 0 1 1 0 2 Low 
8 variables collected: 
Moderate quality 
Vescovi et al. (23) 
2007  2 0 1 1 2 0 0 Low 
9 variables collected: 
Moderate quality  
Van De Wyngeart  
et al. (50) 2008  1 0 1 1 1 0 2 Low 
12 variables collected: 
Good quality 
Stanton et al. (40) 
2009  1 0 1 1 1 0 0 Low 
9 variables collected: 
Moderate quality 
Junquera et al. (19) 
2009  1 0 0 1 1 0 1 Low 
12 variables collected: 
Good quality 
Alons et al. (20)  
2009  1 0 1 1 1 0 0 Low 
12 variables collected: 
Good quality  
Saussez et al. (21) 
2009  1 0 0 1 1 0 2 Low 
11 variables collected: 
Good quality 
Nocini et al. (38)  
2009  1 0 0 1 1 0 0 Medium 
9 variables collected: 
Moderate quality 
Markose et al. (12) 
2009  1 0 1 1 1 0 0 Low 
10 variables collected: 
Good quality 
Stübinger et al. (30) 
2009  1 0 0 1 1 0 0 Medium 
9 variables collected: 
Moderate quality 
Angiero et al. (13) 
2009  2 0 1 1 2 0 0 Low 
9 variables collected: 
Moderate quality 
Epstein et al. (22) 
2010  1 0 0 1 1 0 0 Medium 
9 variables collected: 
Moderate quality 
Stockman et al. (51) 
2010  1 0 1 1 1 0 1 Low 
11 variables collected: 
Good quality 
Williamson  et al. (18) 
2010  1 0 0 1 1 0 0 Medium 
10 variables collected: 
Good quality 
Kos et al. (41)  
2010  2 0 0 1 2 0 2 Low 
12 variables collected: 
Good quality 
Seth et al. (8)  
2010  1 0 0 1 1 0 0 Medium 
8 variables collected: 
Moderate quality 
Hoefert et al. 
(42) 2011  2 0 0 1 2 0 1 Low 
11 variables collected: 
Good quality 
Vescovi et al. (43) 
2011  2 0 1 1 2 0 2 Low 
10 variables collected: 
Good quality 
Bedogni et al. (37) 
2011  1 0 1 1 1 0 2 Low 
11 variables collected: 
Good quality 
Manfredi et al. (16) 
2011  2 0 1 1 2 0 0 Low 
11 variables collected: 
Good quality 
Ferlito et al. (52)  
2011  1 0 1 1 1 0 1 Low 
11 variables collected: 
Good quality 
Ripamonti et al. (31) 
2011  1 0 1 1 1 0 0 Low 
10 variables collected: 
Good quality 
Curi et al. (32) 2011  1 0 1 1 2 0 0 Low 10 variables collected: Good quality 
Atalay et al. (33)  
2011  2 1 0 1 2 0 2 Low 
10 variables collected: 
Good quality 
Jabbour et al. (44) 
2012  1 0 1 1 1 0 1 Low 
10 variables collected: 
Good quality  
Wutzl et al. (9)  
2012  1 0 1 1 1 0 2 Low 
10 variables collected: 
Good quality 
Thumbigere-Math  
et al. (53) 2012  1 0 1 1 1 0 2 Low 
12 variables collected: 
Good quality 
Ferlito et al. (45)  
2012  1 0 1 1 1 0 2 Low 
9 variables collected: 
Moderate quality 
Schubert et al. (46) 
2012  2 0 1 1 2 0 0 Low 
7 variables collected: 
Moderate quality 
Bocanegra-Pérez et al. 
(24) 2012  1 0 1 1 2 0 0 Low 
11 variables collected: 
Good quality 
Martins et al. (25) 
2012  2 0 1 1 2 0 2 Low 
12 variables collected: 
Good quality 
Vescovi et al. (26) 
2012  2 0 0 1 2 0 2 Low 
12 variables collected: 
Good quality 
Mozzatti et al. (34) 
2012  1 0 1 1 2 0 0 Low 
12 variables collected: 
Good quality 
Table 3. Evaluation of risk of bias and usefulness of the selected publications using intravenous bisphosphonates.
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oral bisphosphonates, it is clear that: 1) the partial or 
complete healing of ONJ lesions for each protocol, from 
most to least by percentage of ONJ cured, is: Protocol 
3 (100%) > Protocol 7 (100%) > Protocol 1 (100%) Pro-
tocol 2 (100%) > Protocol 5 (100%); 2) no worsening of 
ONJ lesions was observed in any of these protocols.
Two of the protocols cannot be evaluated for either heal-
ing (partial and/or complete) or worsening of ONJ le-
sions due to different reasons: in Protocol 4 (8-14), the 
articles do not report the effect on ONJ lesions with re-
spect to stage of severity, and in Protocol 6 (15), none of 
the articles describe the effect on ONJ lesions.
According to the results obtained, the protocols that 
obtain the best healing (partial or complete) of ONJ le-
sions are Protocols 3 and 7, with 100% of lesions healed 
(whether partial or complete). Although 100% of lesions 
were healed in all protocols except those that did not 
mention these results, the descending order mentioned 
Beninati et al. (47) 
2013  1 0 1 1 1 0 0 Low 
10 variables collected: 
Good quality 
Holzinger et al. (48) 
2013  1 0 1 1 1 0 2 Low 
8 variables collected: 
Moderate quality 
Anavi-Lev et al. (49) 
2013  1 0 0 1 1 0 2 Low 
10 variables collected: 
Good quality 
Blus et al. (10)  
2013  1 0 1 1 1 0 0 Low 
12 variables collected: 
Good quality 
Rugani et al. (36) 
2013  1 0 0 1 1 0 0 Medium 
9 variables collected: 
Moderate quality 
Hanasono et al. (14) 
2013  2 0 0 1 1 0 0 Medium 
10 variables collected: 
Good quality 
Scoletta et al. (35) 
2013  1 0 1 1 2 0 2 Low 
10 variables collected: 
Good quality 
Melea et al. (54)  
2013  2 0 1 1 2 0 2 Low 
11 variables collected: 
Good quality 
!
PROTOCOLS TOTAL ONJ LE-SIONS
RESULTS OF 
ONJ LESIONS 
TOTAL SUM PERCENTAGE OF 
TOTAL SUM
Protocol 1
 (19,21,22)
1 ONJ lesion Complete healing: 1Partial healing: 0
Worsen: 0
Not documented: 0
Healing (Partial 
and Complete): 1
Worsen: 0
Not documented: 0
Healing (Partial and 
Complete): 100 %
Worsen: 0 %
Not documented: 0 %
Protocol 2
(9,18-20,39-54)
1 ONJ lesion Complete healing: 0Partial healing: 1
Worsen: 0
Not documented: 0
Healing (Partial 
and Complete): 1
Worsen: 0
Not documented: 0
Healing (Partial and 
Complete): 100 %
Worsen: 0 %
Not documented: 0 %
Protocol 3
(16,17,21,23-35) 
7 ONJ lesions Complete healing: 6Partial healing: 1
Worsen: 0
Not documented: 0
Healing (Partial 
and Complete): 7
Worsen: 0
Not documented: 0
Healing (Partial and 
Complete): 100 %
Worsen: 0 %
Not documented: 0 %
Protocol 4
 (8-14) 
No documented 
lesions
No documented 
lesions
No documented 
lesions
No documented le-
sions
Protocol 5
(36-38)
1 ONJ lesion Complete healing: 1Partial healing: 0
Worsen: 0
Not documented: 0
Healing (Partial 
and Complete): 1
Worsen: 0
Not documented: 0
Healing (Partial and 
Complete): 100 %
Worsen: 0 %
Not documented: 0 %
Protocol 6 
(15)
No documented 
lesions
No documented 
lesions
No documented 
lesions
No documented le-
sions
Protocol 7 
(16,21,23,26,36) 
6 ONJ lesions Complete healing: 3Partial healing: 3
Worsen: 0
Not documented: 0
Healing (Partial 
and Complete): 6
Worsen: 0
Not documented: 0
Healing (Partial and 
Complete): 100 %
Worsen: 0 %
Not documented: 0 %
Table 3 continue. Evaluation of risk of bias and usefulness of the selected publications using intravenous bisphosphonates.
Table 4. Overall results of ONJ lesions caused by oral bisphosphonates. 
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above still applies, as Protocol 3 and 7 have seven and 
six lesions, respectively, and the remaining protocols 
(Protocols 1, 2, and 5) have only one. 
However, as the studied articles had few ONJ lesions 
secondary to oral bisphosphonates, care should be taken 
when drawing firm conclusions from these results. 
Focusing on the protocol this study found to be the best, 
Protocol 3 cures 100% of lesions, which coincides with 
the findings of other studies found in the literature that 
reference 89.5% to 91% healing of oral mucosa (16,17). 
This may be due to the minimally invasive surgical 
treatment (curettage or debridement of the exposed site, 
contouring, sequestrectomy with or without teeth in-
volvement, etc.) used in this protocol, with these being 
the most common surgical techniques used in the man-
agement of chemotherapy-associated osteonecrosis of 
the jaw or refractory ONJ (18). In addition, this protocol 
is associated with other strategies such as conservative 
treatment (19) and adjuvant therapies (17), resulting in 
synergistic disease management. Nevertheless, the pro-
tocol’s prognosis may vary according to the stage and 
type of ONJ lesion, and it is not indicated for patients 
at risk of ONJ or in its early stages. This aspect will be 
discussed later.
Regarding the overall effectiveness of the seven proto-
cols observed in the treatment of ONJ lesions caused 
by intravenous bisphosphonates, it is clear that: 1) the 
healing (partial or complete) of ONJ lesions for each 
protocol, following a sequential and descending order 
by percentage of healed ONJ, would be: Protocol 2, 
(100%) > Protocol 3 (85.71%) > Protocol 7 (83.33%) > 
Protocol 5 (66.66%) > Protocol 1 (53.12%); 2) the wors-
ening of ONJ lesions for each protocol in sequential and 
descending order, by percentage of ONJ lesions that got 
worse, is: Protocol 1 (46.87%) > Protocol 5 (33.33%) > 
Protocol 3 (14,28%).
PROTOCOLS TOTAL ONJ LESIONS
RESULTS OF ONJ 
LESIONS
TOTAL SUM PERCENTAGE 
OF TOTAL SUM
Protocol 1
 (19,21,22) 32 ONJ lesions
Complete healing: 10
Partial healing: 7
Worsen: 15
Not documented: 0
Healing (Partial and 
Complete): 17
Worsen: 15
Not documented: 0
Healing (Partial and 
Complete): 53.12 %
Worsen: 46.87 %
Not documented: 
0 %
Protocol 2
(9,18-20,39-54) 10 ONJ lesions
Complete healing: 0
Partial healing: 10
Worsen: 0
Not documented: 0
Healing (Partial and 
Complete): 10
Worsen: 0
Not documented: 0
Healing (Partial and 
Complete): 100 %
Worsen: 0 %
Not documented: 
0 %
Protocol 3
(16,17,21,23-35) 7 ONJ lesions
Complete healing: 6
Partial healing: 0
Worsen: 1
Not documented: 0
Healing (Partial and 
Complete): 6
Worsen: 1
Not documented: 0
Healing (Partial and 
Complete): 85.71 %
Worsen: 14.28 %
Not documented: 
0 %
Protocol 4
 (8-14) No documented lesions
No documented le-
sions No documented lesions
No documented 
lesions
Protocol 5
(36-38) 6 ONJ lesions
Complete healing: 4
Partial healing: 0
Worsen: 2
Not documented: 0
Healing (Partial and 
Complete): 4
Worsen: 2
Not documented: 0
Healing (Partial and 
Complete): 66.66 %
Worsen: 33.33 %
Not documented: 
0 %
Protocol 6 
(15) No documented lesions
No documented le-
sions No documented lesions
No documented 
lesions
Protocol 7 
(16,21,23,26,36) 6 ONJ lesions
Complete healing: 5
Partial healing: 0
Worsen: 0
Not documented: 1
Healing (Partial and 
Complete): 5
Worsen: 0
Not documented: 1
Healing (Partial and 
Complete): 83.33 %
Worsen: 0 %
Not documented:
16.66 %
Table 5. Overall results of ONJ lesions caused by intravenous bisphosphonates.
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Stage 0 of ONJ 
 
PROTOCOLS 
 
 
TOTAL ONJ LESIONS 
 
RESULTS OF ONJ LESIONS IN 
STAGE 0 
Protocol 1 
 (19,21,22) 
 
1 ONJ lesion 
 
There are no lesions in Stage 0 
Protocol 2 
(9,18-20,39-54) 
 
1 ONJ lesion 
 
There are no lesions in Stage 0 
Protocol 3 
(16,17,21,23-35)  
 
7 ONJ lesions 
 
There are no lesions in Stage 0 
Protocol 4 
 (8-14)  
 
No documented lesions 
 
No documented lesions 
Protocol 5 
(36-38) 
 
1 ONJ lesion 
 
No patients treated with oral BP 
Protocol 6  
 (15) 
 
No documented lesions 
 
No documented lesions 
Protocol 7  
(16,21,23,26,36)  
 
6 ONJ lesions 
 
No patients treated with oral BP 
Stage 1 of ONJ 
 
PROTOCOLS 
 
 
TOTAL ONJ LESIONS 
 
RESULTS OF ONJ LESIONS IN 
STAGE 1 
Protocol 1 
 (19,21,22) 
 
1 ONJ lesion 
1 patient treated with oral BP (Alend):  
1 ONJ lesion in Stage 1 
Complete healing: 1  
Protocol 2 
(9,18-20,39-54) 
 
1 ONJ lesion 
 
No patients treated with oral BP 
Protocol 3 
(16,17,21,23-35)  
 
7 ONJ lesions 
1 patient treated with oral BP (Clod):  
1 ONJ lesion in Stage 1 
Complete healing: 1  
Protocol 4 
 (8-14)  
 
No documented lesions 
 
No documented lesions 
Protocol 5 
(36-38) 
 
1 ONJ lesion 
 
No patients treated with oral BP 
There are no lesions in Stage 1 
Protocol 6  
 (15) 
 
No documented lesions 
 
No documented lesions 
Protocol 7  
(16,21,23,26,36)  
 
6 ONJ lesions 
 
No patients treated with oral BP 
There are no lesions in Stage 1  
Stage 2 of ONJ 
 
PROTOCOLS 
 
 
TOTAL ONJ LESIONS 
 
RESULTS OF ONJ LESIONS IN 
STAGE 2 
Protocol 1 
 (19,21,22) 
 
1 ONJ lesion 
 
No patients treated with oral BP 
Protocol 2 
(9,18-20,39-54) 
 
1 ONJ lesion 
1 patient treated with oral BP (Alend):  
1 ONJ lesion in Stage 2 
Partial healing: 1 
Protocol 3 
(16,17,21,23-35)  
 
7 ONJ lesions 
6 patients treated with oral BP (Alend):  
6 ONJ lesions in Stage 2 
Complete healing: 5 
Partial healing: 1 
Protocol 4 
 (8-14)  
 
No documented lesions 
 
No documented lesions 
Protocol 5 
(36-38) 
 
1 ONJ lesion 
1 patient treated with oral BP (Alend): 
1 ONJ lesion in Stage 2 
Complete healing: 1 
Table 6. Results of lesions according to protocol and stage of ONJ caused by oral bisphosphonates. 
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Two of the protocols cannot be evaluated for either heal-
ing (partial and complete) or worsening of ONJ lesions 
due to different reasons: 1) in Protocol 4 (8-14), none 
of the articles give results on ONJ lesions according to 
their stage of severity; and 2) in Protocol 6 (15), none of 
the studies describe the effects on ONJ lesions. 
According to the results obtained, the protocols that 
obtain the best healing (partial or complete) of ONJ le-
sions are Protocols 2, 3, and 7, with 100%, 85%, 71%, 
and 83.33%, of lesions healed (whether partial or com-
plete), respectively. With regard to worsening lesions, 
Protocol 1 had the highest number of worsened lesions, 
at 46.87%, and Protocol 5 had a rate of 33.33%.
The protocol with best results, Protocol 2, achieves a 
100% lesion healing rate, comparable with the results of 
other published studies in which healing of oral mucosa 
was seen in 90% of the patients (20); however, not all 
studies obtained such results, with some only obtaining 
58.5% of completely covered mucosa (9). This protocol 
is based on conservative treatment and minimally inva-
sive surgical techniques, as previously seen in Protocol 
3, with the only difference between Protocols 2 and 3 
being the use of adjuvant therapies in the latter. As a 
result, the second best results were seen from Protocol 
3, with 85.71% of lesions healed. However, as discussed 
below, its prognosis may vary according to the stage of 
the ONJ lesion. 
Regarding the effectiveness of the results obtained us-
ing the seven protocols in the treatment of ONJ lesions 
caused by oral bisphosphonates, as evaluated in each of 
the different stages, it can be indicated that: 1) in Stage 
0, no ONJ lesions were treated with the mentioned 
protocols in patients receiving orally administered bi-
sphosphonates; 2) in Stage I (19,21,22), both Protocol 1 
and Protocol 3 (16,17,21,23-35) obtained the best results; 
3) in Stage II, the protocol with the best rate of healing 
is Protocol 3, (16,17,21,23-35) followed by Protocols 7, 
(16,21,23,26,36) 5, (36-38) y 2; (9,18-20,39-54) 4) in Stage 
III, no ONJ lesions were treated with the mentioned pro-
tocols in patients taking oral bisphosphonates.
In both Stage 0 and Stage III, there no ONJ lesions 
caused by oral bisphosphonates were observed; there-
fore, it is impossible to know which protocol obtains 
the best results. Consequently, Stages I and II can be 
assessed. In Stage I, the best results were seen in Proto-
cols 1 and 3, and these protocols were the only ones in 
which lesions were recorded as completely cured, with 
one lesion identified per protocol. In Stage II, the proto-
col with the best results is Protocol 3, followed by Pro-
tocol 7. However, due to the limited number of lesions 
observed in each stage and treatment protocol for ONJ 
lesions caused by oral bisphosphonates, it would not be 
realistic to establish a valid uniform approach. It is true 
that the results obtained in Stage II could potentially be 
discussed further, with Protocol 3 being a therapeutic 
alternative with optimal results.
In regards to the effectiveness of the results obtained by 
the seven protocols in the treatment of each of the stages 
Protocol 6  
 (15) 
 
No documented lesions 
 
No documented lesions 
Protocol 7  
(16,21,23,26,36)  
 
6 ONJ lesions 
6 patients treated with oral BP (Alend): 
6 ONJ lesions in Stage 2 
Complete healing: 3 
Partial healing: 3  
Stage 3 of ONJ 
 
PROTOCOLS 
 
 
TOTAL ONJ LESIONS 
 
RESULTS OF ONJ LESIONS IN 
STAGE 3 
Protocol 1 
 (19,21,22) 
 
1 ONJ lesion 
 
No patients treated with oral BP 
Protocol 2 
(9,18-20,39-54) 
 
1 ONJ lesion 
 
No patients treated with oral BP 
Protocol 3 
(16,17,21,23-35)  
 
7 ONJ lesions 
 
No patients treated with oral BP 
Protocol 4 
 (8-14)  
 
No documented lesions 
 
No documented lesions 
Protocol 5 
(36-38) 
 
1 ONJ lesion 
 
No patients treated with oral BP 
Protocol 6  
 (15) 
 
No documented lesions 
 
No documented lesions 
Protocol 7  
(16,21,23,26,36)  
 
6 ONJ lesions 
 
No patients treated with oral BP 
!
Table 6 continue. Results of lesions according to protocol and stage of ONJ caused by oral bisphosphonates. 
Med Oral Patol Oral Cir Bucal. 2017 Jan 1;22 (1):e43-57.                                                                                                              Therapeutic protocols for oral administration and bisphosphonates
e53
Stage 0 of ONJ 
 
PROTOCOLS 
 
 
TOTAL ONJ LESIONS 
 
RESULTS OF ONJ LESIONS IN 
STAGE 0 
Protocol 1 
 (19,21,22) 32 ONJ lesions There are no lesions in Stage 0 
Protocol 2 
(9,18-20,39-54) 10 ONJ lesions There are no lesions in Stage 0 
Protocol 3 
(16,17,21,23-35)  7 ONJ lesions There are no lesions in Stage 0 
Protocol 4 
 (8-14)  No documented lesions No documented lesions 
Protocol 5 
(36-38) 
 
6 ONJ lesions 
2 patients treated with IV BP  
(Zoled, Iban)  
2 ONJ lesions in Stage 0 
Complete healing: 2 
Protocol 6  
(15) No documented lesions No documented lesions 
Protocol 7  
(16,21,23,26,36)  
 
6 ONJ lesions 
5 patients treated with IV BP  
(Zoled, Iban) 
5 ONJ lesions in Stage 0 
Complete healing: 5 
Stage 1 of ONJ 
 
PROTOCOLS 
 
 
TOTAL ONJ LESIONS 
 
RESULTS OF ONJ LESIONS IN 
STAGE 1 
Protocol 1 
 (19,21,22) 
 
32 ONJ lesions 
9 treated with IV BP  
(Zoled, Pam, Iban or combined) 
9 ONJ lesions in Stage 1 
Complete healing: 3 
Partial healing: 2 
Worsen: 4 
Protocol 2 
(9,18-20,39-54) 10 ONJ lesions 
2 patients treated with IV BP (Zoled)  
2 ONJ lesions in Stage 1 
Partial healing: 2  
Protocol 3 
(16,17,21,23-35)  7 ONJ lesions 
There are not patients treated with IV 
BP 
There are no lesions in Stage 1 
Protocol 4 
 (8-14)  No documented lesions 
 
No documented lesions 
Protocol 5 
(36-38) 6 ONJ lesions 
There are not patients treated with IV 
BP 
There are no lesions in Stage 1 
Protocol 6  
(15) No documented lesions                No documented lesions 
Protocol 7  
(16,21,23,26,36)  6 ONJ lesions 
 
There are not patients treated with IV 
BP 
There are no lesions in Stage 1  
Stage 2 of ONJ 
 
PROTOCOLS 
 
 
TOTAL ONJ LESIONS 
 
RESULTS OF ONJ LESIONS IN 
STAGE 2 
Protocol 1 
 (19,21,22) 
 
32 ONJ lesions 
21 treated with IV BP  
(Zoled,Pam, Iban or combined) 
21 ONJ lesions in Stage 2 
Complete healing: 6 
Partial healing: 5 / Worsen: 10 
Protocol 2 
(9,18-20,39-54) 
 
10 ONJ lesions 
3 patients treated with IV BP  
(Zoled, Iban) 
3 ONJ lesions in Stage 2 
Partial healing: 3  
Table 7. Results of lesions according to protocol and stage of ONJ caused by intravenous bisphosphonates.
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of ONJ lesions caused by intravenous bisphosphonates, 
it can be indicated that: 1) in Stage 0, Protocol 7 had 
the best results (16,21,23,26,36), followed by Protocol 
5;(36-38) 2) in stage I, the best protocol was Protocol 
1 (36-38), followed by Protocol 2; (9,18-20,39-54) 3) in 
Stage 2, the best protocol by rate of healing is Protocol 
1, (19,21,22) followed by Protocols 3, (16,17,21,23-35) 5, 
(36-38) and 2; (9,18-20,39-54) 4) in Stage III, Protocol 1 
had the best results (19,21,22), followed by Protocol 2 
(9,18-20,39-54).
In stage 0, Protocol 7 obtained the best results, with five 
ONJ lesions treated with this protocol and 100% of the 
lesions cured completely. This may be because in early 
stages with unspecific radiological and clinical symp-
tomatology and without necrotic bone exposure, the 
clinical and radiological follow-up, conservative treat-
ment, and use of adjuvant therapies can be enough to 
keep the lesion stable so it does not progress and to pro-
mote remission of symptoms. These results match those 
found in the literature, as for example the study carried 
out by Rugani, (17) who found that a combination of oral 
mouthwashes, medical treatment and photodynamic 
therapy can promote secondary granulation and the for-
mation of new scar mucosa. This combination would 
avoid more aggressive therapies and more advanced 
stages of ONJ, thereby achieving optimal results.
In ONJ Stages I, II and III, Protocol I obtained the best 
results, followed by Protocol 2 in Stages I and II, and 
Protocol 3 in Stage III. The rates of healing of ONJ le-
sions using Protocol 1 in ONJ Stages I, II and III are 
55.55%, 52.38%, and 100%, respectively. These results 
match those found in the literature (around 57% of 
cured lesions and/or healed). (21) However, the obtained 
results show only Stage III lesion treated with Protocol 
1, which was fully cured; therefore it is not especially 
substantial evidence. This should be taken into account 
when choosing between Protocols 1 and 3. 
With regard to Protocol 1 therapy for Stages I and II, 
five out of nine lesions were cured, either partially or 
completely. If all protocols are included, in Stage I and 
Stage II, 11 out of 21 lesions were cured, either partially 
or completely. In these two stages (I and II), Protocol 1 
Protocol 3 
(16,17,21,23-35)  
 
7 ONJ lesions 
6 patients treated with IV PB  
(Zolen, Pam, Clod) 
6 ONJ lesions in Stage 2 
Complete healing: 6 
Protocol 4 
 (8-14)  No documented lesions 
 
No documented lesions 
Protocol 5 
(36-38)                   6 ONJ lesions 
3 patients treated with IV BP (Zolen)  
3 ONJ lesions in Stage 2 
Complete healing: 2 / Worsen: 1 
Protocol 6  
(15) No documented lesions               No documented lesions 
Protocol 7  
(16,21,23,26,36)  
 
6 ONJ lesions 
1 patient treated with IV BP (Pam) 
1 ONJ lesion in Stage 2 
Not documented: 1  
Stage 3 of ONJ 
             
            PROTOCOLS 
 
       TOTAL ONJ LESIONS RESULTS OF ONJ LESIONS IN     STAGE 3 
                   Protocol 1 
 (19,21,22) 
 
32 ONJ lesions 
2 patients treated with IV BP (Zoled) 
2 ONJ lesions in Stage 3 
Complete healing: 1 / Worsen: 1 
Protocol 2 
(9,18-20,39-54) 
 
10 ONJ lesions 
5 patients treated with IV BP  
(Zoled, Iban) 
5 ONJ lesions in Stage 3 
Partial healing: 5 
Protocol 3 
(16,17,21,23-35)  7 ONJ lesions 
1 patient treated with IV BP (Pam) 
1 ONJ lesion in Stage 3 /Worsen: 1 
Protocol 4 
 (8-14)  No documented lesions 
 
No documented lesions 
Protocol 5 
(36-38) 6 ONJ lesions 
1 patient treated with IV BP (Zolen)  
Worsen: 1 
Protocol 6  
(15) No documented lesions              No documented lesions 
Protocol 7  
(16,21,23,26,36)  6 ONJ lesions 
There are not patients treated with IV 
BP 
!
Table 7 continue. Results of lesions according to protocol and stage of ONJ caused by intravenous bisphosphonates.
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can be identified as a potentially effective therapeutic 
tool.
Returning to discussion of the overall results, Pro-
tocol 1 paradoxically saw greater worsening of ONJ 
lesions overall, but for some stages, it obtained more 
partial and complete healing. During the early stages 
of the disease, a conservative approach in the treat-
ment of chemotherapy-associated osteonecrosis of 
the jaw, which prioritizes the etiological treatment of 
symptomatology (analgesics, antibiotics, antifungals, 
mouthwashes, and treatment discontinuation) along-
side clinical and radiological follow-up, is usually the 
first step in ONJ management because it promotes 
promising results, given the complexity of accurate 
and successful treatment of ONJ.
However, the effectiveness of each treatment and pro-
tocol may vary according to the stage ONJ (early or 
advanced), developed symptomatology, type of bony 
sequestrum, patient characteristics (medical and dental 
history), and different risk factors associated with ONJ. 
It is important to control all of these parameters in order 
to keep the disease from progressing to advanced stages 
(1-4). 
While there are various different protocols for the man-
agement of ONJ, the best way to fight the disease is by 
preventing it, as this is the most ideal stage with guar-
anteed success, thereby improving quality of life in pa-
tients treated with bisphosphonates. 
To conclude, it is clear that: 1) There are different thera-
peutic options for managing osteonecrosis of the jaw, 
such as conservative treatment, minimally invasive 
surgical treatment, invasive surgical treatment, and ad-
juvant therapies, which have been grouped in seven dif-
ferent protocols for the purposes of the present study. 2) 
Due to the small number of ONJ lesions caused by oral 
bisphosphonates, it is not possible to establish relevant 
criteria, hence there is a need for more studies with a 
higher number of ONJ lesions caused by orally admin-
istered bisphosphonates before reaching firm conclu-
sions. 3) According to the seven grouped protocols and 
their obtained results, it can be stated that the best ap-
proach for ONJ lesions caused by oral bisphosphonates 
is Protocol 3, while the best option for lesions caused by 
intravenous bisphosphonates is Protocol 2. 4) Accord-
ing to the seven grouped protocols and their obtained 
results in each stage of ONJ, the protocol that resulted 
in better healing of Stage 1 ONJ lesions caused by oral 
bisphosphonates is Protocol 1, and Protocol 3 in Stage 
II (in Stages 0 and III, the consulted data does not detail 
any ONJ lesions caused by oral bisphosphonates). 5) Re-
garding ONJ lesions secondary to intravenous bisphos-
phonates, the protocol that obtained the best results in 
Stage 0 is Protocol 7, and in Stages I, II, and II, Protocol 
1 is the best choice.
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